These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 27557862)
1. The Use of Telmisartan and the Incidence of Cancer. Tascilar K; Azoulay L; Dell'Aniello S; Bartels DB; Suissa S Am J Hypertens; 2016 Dec; 29(12):1358-1365. PubMed ID: 27557862 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Sipahi I; Debanne SM; Rowland DY; Simon DI; Fang JC Lancet Oncol; 2010 Jul; 11(7):627-36. PubMed ID: 20542468 [TBL] [Abstract][Full Text] [Related]
3. Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. Dial S; Nessim SJ; Kezouh A; Benisty J; Suissa S Br J Clin Pharmacol; 2014 Nov; 78(5):1151-8. PubMed ID: 24803383 [TBL] [Abstract][Full Text] [Related]
4. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Kowall B; Stang A; Rathmann W; Kostev K Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313 [TBL] [Abstract][Full Text] [Related]
5. Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts. Cardwell CR; Mc Menamin ÚC; Hicks BM; Hughes C; Cantwell MM; Murray LJ BMC Med; 2014 Feb; 12():28. PubMed ID: 24521426 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340 [TBL] [Abstract][Full Text] [Related]
7. Telmisartan, ramipril, or both in patients at high risk for vascular events. ; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. Chang CH; Lin JW; Wu LC; Lai MS J Clin Oncol; 2011 Aug; 29(22):3001-7. PubMed ID: 21690476 [TBL] [Abstract][Full Text] [Related]
9. Risk of cancer associated with the use of angiotensin II-receptor blockers. Olin JL; Veverka A; Nuzum DS Am J Health Syst Pharm; 2011 Nov; 68(22):2139-46. PubMed ID: 22058100 [TBL] [Abstract][Full Text] [Related]
10. Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients. Hicks BM; Murray LJ; Hughes C; Cardwell CR Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):830-40. PubMed ID: 26017274 [TBL] [Abstract][Full Text] [Related]
11. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ARB Trialists Collaboration J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417 [TBL] [Abstract][Full Text] [Related]
12. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. Azoulay L; Eberg M; Benayoun S; Pollak M JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177 [TBL] [Abstract][Full Text] [Related]
13. Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Baumhäkel M; Böhm M Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin II receptor blockers for the treatment of heart failure: a class effect? Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Xi GL; Cheng JW; Lu GC Am J Hypertens; 2008 May; 21(5):546-52. PubMed ID: 18437146 [TBL] [Abstract][Full Text] [Related]
16. Telmisartan: a different angiotensin II receptor blocker protecting a different population? Burnier M J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database . Fujimoto M; Kanou M; Hosomi K; Takada M Int J Clin Pharmacol Ther; 2017 Apr; 55(4):295-303. PubMed ID: 28079518 [TBL] [Abstract][Full Text] [Related]
18. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Yamagishi S; Takenaka K; Inoue H Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710 [TBL] [Abstract][Full Text] [Related]
19. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305 [TBL] [Abstract][Full Text] [Related]
20. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Chan YX; Knuiman MW; Divitini ML; Brown SJ; Walsh J; Yeap BB Eur J Endocrinol; 2017 Oct; 177(4):297-308. PubMed ID: 28684452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]